Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Daniel Sing-Kwong Tsze, Columbia University
ClinicalTrials.gov Identifier:
NCT01549002
First received: February 2, 2012
Last updated: June 30, 2013
Last verified: June 2013

February 2, 2012
June 30, 2013
January 2012
April 2013   (final data collection date for primary outcome measure)
Score on the Observational Scale of Behavioral Distress Revised (OSBD-R) [ Time Frame: Up to 10 minutes after the procedure completion ] [ Designated as safety issue: No ]
Our primary outcome is the Observational Scale of Behavioral Distress - Revised (OSBD-R) to assess observed intra-procedural pain. All enrolled subjects will be videotaped for the OSBD-R, and recordings will be independently reviewed by two study investigators, both blinded to study drug administration. They will each assign an OSBD-R score during four phases of the patient encounter: (1) before analgesia administration, (2) ten minutes after analgesia administration, (3) during I&D procedure, (4) ten minutes after procedure completion. An inter-investigator kappa statistic will be obtained.
Same as current
Complete list of historical versions of study NCT01549002 on ClinicalTrials.gov Archive Site
  • Score on the Faces Pain Scale Revised (FPS-R) [ Time Frame: Up to 10 minutes after procedure completion ] [ Designated as safety issue: No ]
    The Faces Pain Scale Revised (FPS-R) has been validated in patients 4 - 16 years of age undergoing painful procedures and will be used to assess patients' self reported pain. Patients will complete the FPS-R at four times during their medical encounter: (1) before analgesia administration, (2) ten minutes after analgesia administration but before beginning I&D, (3) immediately post I&D procedure (to ascertain the pain perceived during procedure), and (4) ten minutes after procedure completion.
  • Score on Likert Scale for patient satisfaction [ Time Frame: 10 minutes after procedure completion ] [ Designated as safety issue: No ]
    Patient satisfaction will be measured on a Likert scale just prior to Emergency Department discharge. If the patient is 8 years of age and older, both the patient and the parent or guardian will complete a satisfaction survey. If the patients is younger than 8 years, their parent or guardian will complete the satisfaction survey.
Same as current
Not Provided
Not Provided
 
Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children
Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children

Children can develop abscesses (a collection of pus under their skin) that require a physician to cut it open to let the pus drain out. This is a painful procedure. Most medical professionals will use numbing cream and inject numbing medicine into the skin, just like at the dentist, to help reduce the pain. While this helps minimize the pain of cutting the skin, it doesn't help the pain associated with draining out the pus.

There are many strategies and medications available to physicians to help decrease the pain of this procedure. Most of the medications available to treat the pain require the placement of an intravenous (IV) catheter through the patient's skin, which itself is a painful procedure. In the investigators emergency department, many patients with abscesses that need a procedure to drain the pus receive a medicine called morphine through an IV.

Some pain medicines, however, can be sprayed into a patient's nose, and have been shown to be helpful at reducing the pain of a broken bone or a burn. These medicines do not require the placement of an IV.

The purpose of this research study is to determine whether a medicine called fentanyl, when sprayed into the nose of patients aged 4 to 18 years undergoing abscess drainage, is not worse than IV morphine in decreasing the pain of the procedure.

After the risks and benefits of the study are explained to patients and their parents, written informed consent will be obtained. Written informed assent will be obtained for patients older than 8 years of age. Like the flipping of a coin, a computer program will decide randomly which half of the patients will receive fentanyl nose spray and which half will receive morphine by IV.

The patients assigned to receive fentanyl nose spray will not have an IV placed. The patients assigned to receive morphine will have an IV placed. Both groups of patients will have the abscess drainage procedure done the same way. All patients will be videotaped in order to score their pain by a trained observer. This score is the main outcome (measurement) in the study.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
  • Abscess
  • Pain
  • Drug: Intranasal Fentanyl
    Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose
  • Drug: Intravenous Morphine
    Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose
  • Experimental: Intranasal Fentanyl

    Patients in this arm will receive intranasal Fentanyl (50 micrograms/mL) as their pre-I&D analgesic. The one time total dose to be used is 2 micrograms / kilogram, to a maximum of 100 micrograms. The medication will be delivered intranasally via an atomizer in 4 equally divided aliquots (2 per nare).

    The abscess I&D will be followed according to protocol using topical and local anesthetic.

    Intervention: Drug: Intranasal Fentanyl
  • Active Comparator: Intravenous Morphine

    Patients in this arm will receive intravenous morphine as their pre-I&D analgesic. The one time total dose to be used is 0.1 milligrams / kilogram, to a maximum of 8 milligrams. The medication will be delivered via slow IV push.

    The abscess I&D will be followed according to protocol using topical and local anesthetic.

    Intervention: Drug: Intravenous Morphine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
April 2013
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient is 4 years of age up to their 18th birthday
  • Patient has a cutaneous abscess for which an I&D is to be performed

Exclusion Criteria:

  • Patient's parent doesn't speak English or Spanish
  • Patient has developmental delay or neurological impairment
  • Patient has altered mental status
  • Known hypersensitivity to study drugs (fentanyl, morphine sulfate, lidocaine, LMX4®)
  • The presence of significant blood or mucous in the nares despite blowing nose or suctioning
  • Severe renal or liver dysfunction, signs of respiratory distress or depression, any respiratory distress, chronic and severe asthma, upper airway obstruction, suspected gastrointestinal obstruction, suspected paralytic ileus
  • Narcotic analgesia within 4 hours of ED physician evaluation
  • Need for moderate sedation, deep sedation, or general anesthesia
  • Need for subspecialty consultation to perform the I&D
  • Need for I&D of more than 1 skin abscess
  • Cutaneous abscesses located on the genitals, breasts, face, or neck
  • Previous enrollment in the study
  • Patients with chronic pain syndromes (sickle cell disease, cancer, arthritis, inflammatory bowel disease)
Both
4 Years to 18 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01549002
AAAI0699
Yes
Daniel Sing-Kwong Tsze, Columbia University
Columbia University
Not Provided
Principal Investigator: Daniel Tsze, MD, MPH Columbia University
Study Director: Peter Dayan, MD, MSc Columbia University
Principal Investigator: Daniel Fenster, MD Columbia University
Columbia University
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP